- Home
- ENPH vs XENE Comparison
ENPH vs XENE Comparison
Compare ENPH & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENPH | XENE |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.2B |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ENPH | XENE |
|---|---|---|
| Price | $63.74 | $53.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 11 |
| Target Price | $41.30 | ★ $68.55 |
| AVG Volume (30 Days) | ★ 8.8M | 996.9K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,985,000.00 | $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.81 | $2,496.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $25.78 | $29.74 |
| 52 Week High | $73.74 | $62.91 |
Technical Indicators
Market Signals| Indicator | ENPH | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 41.29 |
| Support Level | $32.08 | $52.90 |
| Resistance Level | N/A | $59.43 |
| Average True Range (ATR) | 5.97 | 1.49 |
| MACD | 1.87 | -0.12 |
| Stochastic Oscillator | 74.49 | 17.72 |
Price Performance
Historical ComparisonAbout ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.